Sigilon Therapeutics is a clinical stage biotechnology company developing a class of therapeutics and functional cures for patients with chronic diseases. Co.'s product candidates include: SIG-005, which treats the non-neurological manifestations of mucopolysaccharidosis type 1 in patients with the disease; SIG-007, which provides continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; SIG-002, which is designed to replace islet cells for the treatment of Type 1 Diabetes; and SIG-001, which prevents bleeding episodes in patients with moderate to severe Hemophilia A. The SGTX average annual return since 2020 is shown above.
The Average Annual Return on the SGTX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SGTX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SGTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|